BCMA CAR-T Updates at ASCO 2020 – Ide-cel, Orva-cel, JNJ-4528
Three key oral presentations for BCMA CAR-Ts were presented at ASCO 2020: ide-cel (Ph2 KarMMa) and orva-cel (Ph1/2 EVOLVE) from BMS, and JNJ-4528 (Ph1b/2 CARTITUDE-1) from Janssen. All three studies evaluated CAR-T cells in ≥4L RRMM patients. Below, FENIX provides key data highlights and analysis on the competitiveness of each CAR-T.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.